New research unveils a groundbreaking quintuple agonist that targets multiple pathways for effective treatment of obesity and ...

Eli Lilly and Company (NYSE: LLY) today announced detailed results from SURPASS-PEDS, the first Phase 3 trial to evaluate the ...

Much excitement has built in recent years on the new class of incretin drugs that include glucagon-like-peptide-1 inhibitors ...

Much excitement has built in recent years on the new class of incretin drugs that include glucagon-like-peptide-1 inhibitor ...

Dr Shivani Misra is a clinical associate professor and honorary consultant in diabetes at Imperial College London ...

A compound comprising five agonists that together tackle weight loss, glucose reduction, insulin sensitization, and blood fat ...

Medical experts discuss whether GLP-1 medications, including Mounjaro and Zepbound, could become comprehensive treatments for ...

The WHO has added GLP-1 agonists to its Essential Medicines List in 2025. Learn more about the impact of this decision.

HELLO! explores Mounjaro side effects and what to expect when you come off the drug, based on the latest clinical guidance ...

Mounjaro shows promise for young patients with Type 2 diabetes and obesity. A recent study reveals its active ingredient, ...

Lilly's GIP/GLP-1 dual receptor agonist, Mounjaro reduces A1C by an average of 2.2% in phase 3 trial of children and adolescents with type 2 diabetes: Indianapolis Friday, Septemb ...

USA: Researchers have reported a potential risk of severe hypercalcemia when tirzepatide, a dual GIP and GLP-1 receptor ...